The third phase of clinical trials of the COVID-19 vaccine “Konvasel” may begin in late summer. It is reported by TASS with reference to the Federal Medical and Biological Agency.
It is emphasized that international research will also begin, for this, centers in other countries will be involved.
Developed by the St. Petersburg Research Institute of Vaccines and Serums, the Konvasel vaccine does not cause allergies and is well tolerated by humans. On April 5, industrial production of the drug was launched. The capacity will allow to produce up to two million doses of vaccine per month.
